Business
TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the American
About this update from Tg Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held virtually June 4 – 8, 2021 and the European Hematology Association (EHA) annual congress, to be held virtually June 9 – 17, 2021. Details of the data presentations are included below. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are excited to share updated data for TG-1701, our novel BTK inhibitor, as a monotherapy, and as a triple therapy with U2, at the upcoming ASCO and EHA annual congresses. The EHA abstract released yesterday included an update from the data most recently presented at the ASH 2020 congress, and we are pleased to see with additional patients and longer follow-up the data continue to show TG-1701 to be efficacious and generally well tolerated in combination with U2. We look forward to updating the abstract data and presenting at both the upcoming ASCO and EHA annual congresses.” Data to be presented at the ASCO meeting: Presentation Title: TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Chronic Lymphocytic Leukemia (CLL) and Lymphoma Abstract ID: 7525Available on Demand: Friday, June 4, 2021 at 9:00 AM ETSession Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic LeukemiaLead Author: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School, University of Western Australia, Crawley, Western Australia The above abstract will be available on May 19, 2021, via the ASCO meeting website at www.asco.org. Data to be presented at the EHA meeting: Presentation Title: TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ubituximab and Umbralisib (U2) in Chronic Lymphocytic Leukemia (CLL) and Lymphoma Abstract Code: EP638Available on Demand: Friday, June 11, 2021 at 9:00 CESTSession Title: Chronic lymphocytic leukemia and related disorders - ClinicalLead Author: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School,...